A New Frontier: Targeted Therapy and Immunotherapy in Bowel Cancer

The treatment landscape for bowel cancer is evolving. For Australians diagnosed with early-onset bowel cancer, this evolution brings both hope and complexity. While surgery, chemotherapy, and radiation still play a major role, newer therapies (like targeted therapy and immunotherapy) are opening the door to more personalised and potentially more effective options.

It’s an exciting shift. But what exactly do these therapies involve? And are they available to younger Australians facing a bowel cancer diagnosis?

What Is Targeted Therapy?

Unlike traditional chemotherapy, which hits all fast-dividing cells (both cancerous and healthy), targeted therapy focuses on specific molecules or pathways that cancer cells depend on to grow, divide, and spread.

It’s not a blanket option. Targeted therapies are matched to the individual characteristics of your tumour, mainly its genetic mutations.

Common Genetic Targets in Bowel Cancer

• RAS (KRAS and NRAS) mutations: These genes affect cell signalling. If a tumour has a RAS mutation, certain targeted therapies like EGFR inhibitors usually won’t work.
• BRAF mutations: Especially BRAF V600E. Found in about 10% of colorectal cancers, it’s linked to a poorer outlook but also opens the door to targeted treatment combos.
• HER2 amplification: Less common, but it can make you eligible for HER2-targeted drugs.
• MSI-H or dMMR: Tumours with these traits tend to respond better to immunotherapy than targeted drugs.

To find out if these apply to your case, your tumour needs to be tested. Medicare covers some tests in certain situations, but even if yours isn’t automatically covered, ask your team about it. Especially if you’re diagnosed young.

Examples of Targeted Therapy in Bowel Cancer

• Anti-EGFR therapy (e.g. cetuximab, panitumumab): Works best in RAS wild-type cases (meaning no RAS mutations).
• Anti-VEGF therapy (e.g. bevacizumab): Helps block blood vessels from feeding tumours. It’s often used alongside chemo. (This one’s actually part of the combo I’ve been getting since I started chemo.)
• BRAF inhibitors (e.g. encorafenib): Used with cetuximab in cancers with a BRAF V600E mutation.
• HER2-targeted agents (e.g. trastuzumab and pertuzumab): If your tumour is HER2-positive, these may be on the table, though they’re not yet routine.

Right now, most of these are used in metastatic (stage 4) cases, but research and trials are pushing them into earlier stages too, including for younger patients.

What Is Immunotherapy?

Immunotherapy is a different beast. It helps your immune system recognise and attack cancer. It’s been a game-changer in melanoma and lung cancers, and while it’s not used as widely in bowel cancer, it can be powerful in certain cases.

It’s mostly used in bowel cancers that are MSI-H or dMMR,  tumours that are genetically unstable and easier for the immune system to spot and fight.

Key Types of Immunotherapy in Bowel Cancer

• Checkpoint inhibitors: These block the “off switches” that stop your immune cells from attacking.
  • Examples include pembrolizumab and nivolumab (target PD-1), and ipilimumab (targets CTLA-4).
• Combination therapies: Some regimens use two different checkpoint blockers together.

Who Benefits from Immunotherapy?

In Australia, immunotherapy is currently approved and funded for advanced or metastatic bowel cancer that has dMMR or MSI-H features. It’s especially relevant for:

• People with Lynch syndrome: An inherited condition that’s more common in younger patients and linked to dMMR tumours.
• Other younger patients with high-risk profiles: Genetic counselling might help guide treatment decisions and future planning.

If you don’t fall into the MSI-H/dMMR group, don’t rule out immunotherapy completely. Trials are exploring ways to make it work for more patients, like combining it with chemo, radiation, or gut microbiome tweaks.

How Do I Know if These Therapies Are Right for Me?

• Ask for tumour profiling: RAS, BRAF, MSI, HER2. Knowing these can unlock access to better-targeted treatments.
• Consider a second opinion: Especially from a GI oncology specialist or someone who regularly sees younger patients.
• Explore clinical trials: Check out Australian Cancer Trials or talk to your oncologist about local options.
• Contact Bowel Cancer Australia: They’ve got great resources and can help you advocate for yourself.

Access and Affordability in Australia

Some targeted and immune-based therapies are funded through the PBS. Others might be accessed via:

• Private health insurance
• Compassionate access programs
• Clinical trials
• Paying out of pocket (which can get expensive fast)

If you’re unsure what’s possible, ask for a hospital social worker or care coordinator. They can help untangle what’s available and what might be worth fighting for.

What About Side Effects?

These therapies tend to be a bit kinder than old-school chemo but they still come with side effects.

Common Side Effects of Targeted Therapy

• Skin rash or acne-like breakouts (especially with EGFR drugs)
• Fatigue
• High blood pressure
• Diarrhoea
• Liver issues

Common Side Effects of Immunotherapy

• Fatigue
• Inflammation (colitis, hepatitis, thyroiditis, basically your immune system attacking healthy stuff)
• Skin reactions
• Flu-like symptoms

If anything feels off, speak up early. Most side effects are easier to manage when caught early.

The Future: Precision Medicine and Personalised Care

Here’s the exciting part: bowel cancer isn’t just one disease. It’s a collection of different types, each with its own behaviour. Precision medicine is all about matching the right treatment to the right person.

What’s coming down the pipeline?

• Tumour mutational burden (TMB): More mutations might mean better response to immunotherapy.
• Liquid biopsies: A blood test that tracks tumour DNA. Non-invasive and promising for catching recurrence early.
• CAR T-cell therapy: Still in the experimental stage for bowel cancer, but potentially a game-changer in the future.
• Gut microbiome research: Your gut bugs could influence how well treatment works. Studies are ongoing.

Advocacy and Informed Decision-Making

If you’re under 50 and navigating bowel cancer, you’re probably juggling more than just treatment, work, parenting, relationships. Knowing what’s out there can help you make decisions that fit your life, not just your cancer.

Tips for Advocating for Targeted or Immune-Based Therapies

• Keep your reports and test results organised
• Take questions to your appointments (write them down!)
• Ask about molecular tumour boards if your case is tricky
• Don’t be afraid of second opinions
• Use Bowel Cancer Australia’s support to push for what you need

Final Thoughts

Targeted therapy and immunotherapy are shifting the landscape, especially for younger Australians with aggressive or complex bowel cancers. They’re not the default for everyone (yet), but they offer real hope and personalised options.

If you’re dealing with an advanced diagnosis, a strong family history, or are just looking for more options, start the conversation. These treatments might be closer within reach than you think.